AbbVie Wins Health Canada Approval for Boey

AbbVie's Boey has received approval from Health Canada, according to multiple reports from the company. AbbVie also announced an acquisition of Apogee Therapeutics, which had a positive impact on the company's stock price. This news was announced on June 27, 2026.

AbbVie ABBV notched a regulatory win as Health Canada approved Boey, a botulinum neurotoxin (serotype E) from its Allergan Aesthetics unit, for the temporary improvement of moderate-to-severe frown lines between the eyebrows. Boey is positioned as the first approved serotype E neurotoxin with rapid onset and a shorter duration of effect, a differentiated entrant in the competitive aesthetics market.

The approval lands days after AbbVie agreed to acquire Apogee Therapeutics in a deal valued at roughly $10.9 billion ($135.11 per share in cash), adding the late-stage IL-13 antibody zumilokibart and a broader immunology and respiratory pipeline. Investors responded positively, with the news adding an estimated $18 billion to AbbVie's market value.

Together, the moves reinforce AbbVie's strategy of expanding beyond its Humira legacy across aesthetics and immunology. Key items to watch include the Apogee deal's expected third-quarter 2026 close and any competitive response in the neurotoxin market, where AbbVie's Botox franchise remains the category leader.